Effect of K-MAP on platelet hyperaggregation in diabetic mellitus patients
| Autor: | Hiroko Yasuda, Yasuo Awaya, Seiji Suzuki, Takahiro Sakai, Shiro Iino, Masaaki Higashihara, Manabu D. Yamanaka, Toshitsugu Kariya, Hiroshi Oka, Shoji Kume |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
medicine.medical_specialty
Antiplatelet drug Side effect business.industry medicine.medical_treatment Diabetic mellitus Blood lipids General Medicine Fibrinogen medicine.disease Endocrinology Internal medicine Diabetes mellitus medicine Platelet Diabetic Vascular Complications business medicine.drug |
| Zdroj: | Blood & Vessel. 18:116-121 |
| ISSN: | 1884-2372 0386-9717 |
| DOI: | 10.2491/jjsth1970.18.116 |
| Popis: | K-MAP (p-aminobenzoic acid-N-D-mannoside sodium salt) shows an antiplatelet action by altering prostaglandin metabolism. This study was conducted to elucidate the effect of K-MAP on platelet hyperaggregation in diabetes mellitus (DM) patients.K-MAP (900mg/day) was daily administered for 12 weeks in 39 patients with DM (57.0±11.8 years of age, male 23, female 16). Platelet aggregation β-thromboglobulin (β-TG), platelet 4 (PF-4), plasma 6-keto PGF1α, plasma TXB2, fibrinogen and serum lipids were measured on every 4 weeks.The obtained results were as follows: 1) Platelet hyperaggregation was observed in 20 patients. K-MAP reduced the hyperaggregation to normal level in 13 patients. 2) A linear relationship was found with a high degree of correlation (r=0.925) between β-TG and PF-4. β-TG and PF-4 were significantly decreased by K-MAP treatment. 3) The low level of 6-keto PGF1α was increased, while the high level of TXB2 decreased by K-MAP treatment. 4) The increased fibrinogen and abnormal serum lipids levels were improved to normal levels by K-MAP treatment. 5) No side effect was detected during administration of K-MAP.These results support the usefulness of clinical application of K-MAP as a drug preventing from diabetic vascular complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|